• 3. Special items
• 4. Sales
• 5. Cost of sales
• 6. Cost of materials
• 7. Personnel expenses
• 8. Selling, general and administrative expenses
• 9. Net interest
• 10. Other financial result
• 11. Taxes
• 12. Earnings per share

10. Other financial result

The item other financial result includes the following special expenses and income with regard to the acquisition of APP and its financing:

The CVR awarded to the APP shareholders are traded at the NASDAQ Stock Exchange in the United States. The corresponding liability is therefore valued with the current stock exchange price at the reporting date. This valuation resulted in an income of € 6 million in 2009 (2008: income of € 75 million).

Due to its contractual definition, the issued MEB include derivative financial instruments that have to be measured at fair value. This measurement resulted in an expense (before tax) of € 37 million in 2009 (2008: income of
€ 28 million). However, this measurement does not cause a change of the MEB’s nominal amount of € 554.4 million that has to be settled in ordinary shares of Fresenius Medical Care AG & Co. KGaA (FMC-AG & Co. KGaA) upon maturity, but mainly reflects the share price development of these shares (see note 23, Mandatory Exchangeable Bonds).

Furthermore, in the year 2008, one-time financing expenses in an amount of € 35 million were incurred relating to the APP acquisition.